HLA-C and synovial sarcoma: Our results from the mouse model emphasize that SS may be less affected by requirement of a unique key antigen/MHCII combination but rather may be more influenced by a wider range of overall TCR/peptide/MHC interactions involved in the onset/progression of the disease.